Coterra Energy Inc. (NYSE:CTRA) is one of the Best Cheap Stocks to Buy Right Now. Coterra Energy and Devon Energy announced on February 2 a $58 billion all-stock merger, which would make the combined company one of the largest shale producers in the Permian Basin. Combined, these companies currently produce an equivalent of 1.6 million barrels of oil per day. As part of the deal, Coterra shareholders will receive 0.70 shares for each share held. Devon will effectively own 54% of the combined company. KeyB ...

ONEOK Inc. (NYSE:OKE) is one of the Best Cheap Stocks to Buy Right Now. From January 22 to 28, several firms updated their target prices on ONEOK. Jeremy Tonet at JPMorgan cut his target price on ONEOK to $84 (from $87) and downgraded the rating to “Neutral” (from “Overweight”), citing soft macroeconomic fundamentals. He also added that oil prices would likely need to rise before investor sentiment for this stock improves. Meanwhile, Robert Kad of Morgan Stanley also lowered their target price on ONEOK to ...

Core Insights - The article emphasizes the importance of understanding that past performance does not guarantee future results, highlighting the need for careful analysis before making investment decisions [2][3] Group 1 - The article discusses the lack of any current stock or derivative positions held by the author in the companies mentioned, indicating a neutral stance [1] - It clarifies that the information provided is not a specific offer for products or services, nor does it constitute financial advice [2] - The content is presented as factual and up-to-date, but it does not guarantee accuracy or completeness in the analysis of the subjects discussed [2][3]

Group 1 - Enbridge Inc. Cumulative Redeemable Preferred Shares, Series L (EBBNF) relies on the same underlying cash flow as Enbridge Inc. (ENB) common stock, with preferred dividends being paid before common dividends [1] - The investment strategy mentioned focuses on building a resilient, income-generating portfolio with a long-term growth mindset, primarily through long-only investments [1] - The approach blends dividend-paying equities, REITs, and other income strategies with selective growth opportunities, emphasizing disciplined, fundamentals-driven investing [1]

Core Insights - The article emphasizes the importance of understanding that past performance does not guarantee future results, highlighting the need for careful analysis before making investment decisions [2][3] Group 1 - The article discusses the lack of any current stock or derivative positions held by the author in the companies mentioned, indicating a neutral stance [1] - It clarifies that the information provided is not a specific offer for products or services, nor does it constitute financial advice [2] - The content is presented as factual and up-to-date, but it does not guarantee accuracy or completeness in the analysis of the subjects discussed [2][3]

Core Viewpoint - Enbridge Inc.'s Cumulative Redeemable Preferred Shares, Series L (EBBNF) are linked to the same cash flow as Enbridge Inc. (ENB) common stock, with preferred dividends being prioritized over common dividends [1] Group 1: Company Overview - Enbridge Inc. is a company that offers both common stock and preferred shares, with the latter receiving dividends before the former [1] Group 2: Investment Strategy - A Dubai-based investor focuses on creating a resilient, income-generating portfolio with a long-term growth perspective, primarily utilizing a long-only investment approach [1] - The investment strategy includes blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities [1] - The investor emphasizes disciplined, fundamentals-driven investing, prioritizing capital preservation while compounding returns over time [1]

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On January 30, Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration, seeking accelerated approval for UX111 AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA). The resubmitted BLA addresses the agency’s concerns regarding the drug. The company anticipates up to a six-month review ...

Legend Biotech Corp (NASDAQ:LEGN) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. In a board shakeup last month, Legend Biotech Corp (NASDAQ:LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company’s 2026 annual general meeting, replacing outgoing director Li Zhu. Directors Li Zhu and Yau Wai Man Philip resigned from the board, with Legend Biotech stating that the departures were not related to any disp ...

Atlassian Corp (NASDAQ:TEAM) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On February 2, Canaccord Genuity analyst David Hynes maintained a Buy rating on Atlassian (NASDAQ:TEAM) with a price target of $230. Zeroing in on a disconnect between Atlassian’s current valuation and its fundamentals, the analyst said the company’s stock price is down due to sector-wide multiple compression and AI-related concerns, despite its business performance, resilient growth, and improving margins. Hynes f ...

Trade Desk Inc (NASDAQ:TTD) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On February 2, Cathie Wood’s ARK ETF divested a significant portion of its holdings in Trade Desk Inc (TTD), offloading 1,931,578 shares for nearly $58.6 million. Earlier in the month, Wells Fargo maintained an Equal Weight rating on the stock with a price target of $42. In a research note, Wells Fargo said the sudden resignation of the company’s chief financial officer is a sign of “continued fundamental and narrat ...